Urgent

Antithrombotic therapy in AF undergoing PCI

Triple vs dual therapy · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Patients with atrial fibrillation needing anticoagulation who undergo PCI require careful combination of an oral anticoagulant with antiplatelet therapy. Modern practice minimises triple therapy duration to reduce bleeding while protecting against stent thrombosis and stroke.

Red flags

  • Major or life-threatening bleeding
  • Stent thrombosis (recurrent ischaemia)
  • Very high ischaemic risk (complex/left main PCI)
  • Severe renal impairment affecting DOAC dosing
  • Poor adherence risking both bleeding and thrombosis

Assessment

Differential diagnosis

  • AF plus acute coronary syndrome
  • AF plus elective PCI
  • Mechanical valve plus PCI
  • Prior stroke on anticoagulation plus PCI
  • Venous thromboembolism plus PCI
  • High bleeding-risk anticoagulated patient

Investigations

  • Renal function to guide DOAC dosing
  • FBC for baseline haemoglobin/platelets
  • Assessment of bleeding risk (HAS-BLED, modifiable factors)
  • Confirmation of AF and stroke risk (CHA2DS2-VASc)
  • ECG and angiographic complexity assessment
  • Review of indication for anticoagulation

Management

  • Confirm a genuine ongoing need for oral anticoagulation
  • Use a DOAC rather than warfarin where not contraindicated
  • Give triple therapy (OAC plus aspirin plus clopidogrel) only around the peri-PCI period
  • Keep triple therapy as short as possible — often just until hospital discharge, up to ~1 week
  • Transition to dual therapy: a DOAC plus clopidogrel (drop aspirin early)
  • Continue dual therapy (OAC plus single P2Y12 inhibitor) for up to 12 months after ACS
  • Shorten the antiplatelet component in high bleeding risk
  • Use clopidogrel rather than ticagrelor/prasugrel in combination to limit bleeding
  • Prescribe a proton pump inhibitor for gastroprotection
  • At 12 months, continue oral anticoagulation alone long-term
  • Dose the DOAC appropriately for stroke prevention (not a reduced vascular dose)
  • Review bleeding and ischaemic risk at each visit

Drugs & doses

Apixaban 5 mg PO BD (dose-reduced per criteria) as the anticoagulant
Clopidogrel 75 mg PO OD as the preferred P2Y12 inhibitor in combination
Aspirin 75-100 mg PO OD only during the short triple-therapy phase
Pantoprazole 20-40 mg PO OD for gastroprotection
Continue DOAC monotherapy beyond 12 months

Disposition

Inpatient cardiology management post-PCI with a clear written antithrombotic plan; structured outpatient review of duration and bleeding risk.

Complications & pitfalls

  • Major bleeding (especially gastrointestinal/intracranial)
  • Stent thrombosis
  • Ischaemic stroke
  • Recurrent MI
  • Need for transfusion

Exam pearls

  • Modern trials favour early aspirin withdrawal with DOAC plus clopidogrel to cut bleeding
  • Use a full stroke-prevention DOAC dose, not the lower vascular dose, for AF
  • Clopidogrel is preferred over potent P2Y12 inhibitors in combination therapy
  • Always add a PPI for gastroprotection
  • After 12 months most patients need anticoagulation alone

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.